Clementia Pharmaceuticals Inc.

10 clinical trials · Sponsor

Record	Firm	Date
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (NCT05039515)	Clementia Pharmaceuticals Inc.	2021-12-01
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects (NCT04829773)	Clementia Pharmaceuticals Inc.	2019-01-03
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects (NCT04762355)	Clementia Pharmaceuticals Inc.	2018-08-30
An Efficacy and Safety Study of Palovarotene for the Treatment of MO (NCT03442985)	Clementia Pharmaceuticals Inc.	2018-03-22
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (NCT03312634)	Clementia Pharmaceuticals Inc.	2017-11-30
In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects (NCT02521792)	Clementia Pharmaceuticals Inc.	2015-12-07
Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects (NCT04829786)	Clementia Pharmaceuticals Inc.	2015-09-01
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP) (NCT02322255)	Clementia Pharmaceuticals Inc.	2014-12-18
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) (NCT02279095)	Clementia Pharmaceuticals Inc.	2014-10-09
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects (NCT02190747)	Clementia Pharmaceuticals Inc.	2014-07-14

Track Clementia Pharmaceuticals Inc. automatically

Every clearance here is in the API, with alerts when new ones post.